A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.

Abstract

Psoriasis is a chronic inflammatory skin disorder that affects 2% of the population. Evidence suggests that interleukin (IL)-23 plays a pivotal role in the pathogenesis of psoriasis. Guselkumab is a subcutaneously administered, humanized anti-IL23 monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis. Data from Phase I-III trials in this patient population reveal that guselkumab has proven to be superior to placebo or adalimumab based on achieving a Psoriasis Area and Severity Index (PASI) 90% reduction, or a static Physician Global Assessment (sPGA) score of 0 or 1 from baseline. This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis.

• Authors: Z Nawas, M Hatch, E Ramos, M Liu, Y Tong, A Peranteau, S Tyring
• Journal: Skin therapy letter (Skin Therapy Lett) Vol. 22 Issue 2 Pg. 8-10 (Mar 2017) ISSN: 1201-5989 [Print] Canada
• PMID: 28329405 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Interleukin-23
• guselkumab

Topics

• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Clinical Trials as Topic
• Humans
• Interleukin-23 (antagonists & inhibitors)
• Psoriasis (drug therapy, pathology)
• Severity of Illness Index